Pharmaceutical - Markets & Marketing, Neurological

Filter

Popular Filters

1 to 25 of 123 results

USA files suit against Omnicare for accepting kickbacks from Abbott

23-12-2014

The United States has filed a civil False Claims Act complaint against Omnicare alleging that it solicited…

Abbott LaboratoriesDepakoteLegalMarkets & MarketingNeurologicalOmnicarePharmaceuticalUSA

Court tells Actavis it must continue Namenda IR distribution

Court tells Actavis it must continue Namenda IR distribution

12-12-2014

Ireland-headquartered generic drugmaker Actavis confirmed that Judge Robert Sweet of the US District…

ActavisLegalMarkets & MarketingNamendaNeurologicalPharmaceuticalUSA

Patent cliff means pharma will lose $65 billion by 2019, says report

Patent cliff means pharma will lose $65 billion by 2019, says report

11-12-2014

Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent…

AbilifyAstraZenecaEli LillyGlobalMarkets & MarketingNeurologicalOtsukaPatentsPharmaceuticalSeroquelZyprexa

Most-used agents in US bipolar disorder treatment sector; report

Most-used agents in US bipolar disorder treatment sector; report

24-10-2014

Through analysis of US longitudinal patient-level claims data, Bristol-Myers Squibb and Otsuka’s Abilify…

AbilifyBristol-Myers SquibbCymbaltaDainippon Sumitomo PharmaEli LillyGlaxoSmithKlineLamotrigineLatudaMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

New therapies to treat niche populations will drive Parkinson’s market

New therapies to treat niche populations will drive Parkinson’s market

15-10-2014

The Parkinson’s disease pharmacotherapy market will grow 5% annually from $2.3 billion in 2013 to $3.8…

ACADIA PharmaceuticalsAcorda TherapeuticsCivitas TherapeuticsCVT-301Impax LaboratoriesMarkets & MarketingNeurologicalNuplazidPharmaceuticalRytary

Hikma to distribute Eisai’s Fycompa in Middle East

13-10-2014

Hikma Pharmaceuticals has entered into a partnership with Japanese pharma major Eisai for the distribution…

EisaiFycompaHikma PharmaceuticalsJordanLicensingMarkets & MarketingNeurologicalPharmaceuticalRest of the WorldSaudi Arabia

EyeForPharma Multichannel Marketing Summit 2014: Lundbeck's Tim White on customer interaction, apps and buzzwords

EyeForPharma Multichannel Marketing Summit 2014: Lundbeck's Tim White on customer interaction, apps and buzzwords

19-09-2014

Tim White is head of global customer interaction at Lundbeck. The Pharma Letter spoke to him at the EyeForPharma…

DenmarkInterviewsLundbeckMarkets & MarketingNeurologicalPharmaceutical

Latuda’s arrival better late than never for schizophrenia treatment in the UK, says analyst

12-09-2014

The recent introduction of antipsychotic drug Latuda (lurasidone) into the UK market, three years after…

Dainippon Sumitomo PharmaHealthcareLatudaMarkets & MarketingNeurologicalPharmaceuticalSunovion PharmaceuticalsUK

Lundbeck launches Northera in USA

Lundbeck launches Northera in USA

02-09-2014

Danish CNS specialist Lundbeck said today that Northera (droxidopa) capsules for oral use are now available…

Chelsea TherapeuticsLundbeckMarkets & MarketingNeurologicalNortheraPharmaceuticalUSA

Belsomra could become first-line insomnia therapy, says GlobalData

Belsomra could become first-line insomnia therapy, says GlobalData

18-08-2014

Insomnia treatment Belsomra (suvorexant) from US pharma giant Merck & Co has the potential to become…

BelsomraChemistryCyclopyrrolonesInsomniaMarkets & MarketingMerck & CoNeurologicalOrganic chemistryPharmaceuticalUSA

New treatments will partially compensate for unipolar depression drugs coming out of patent

New treatments will partially compensate for unipolar depression drugs coming out of patent

14-08-2014

New antidepressants and antipsychotics will offset a steep decline in sales following genericization…

Antidepressant therapiesDecision Resources GroupGlobalMarkets & MarketingNeurologicalPharmaceuticalPsychiatryUnipolar depression

Global epileptic anticonvulsants market - 2014-2020

Global epileptic anticonvulsants market - 2014-2020

16-07-2014

North America dominates the global epileptic anticonvulsants market and is followed by Europe, according…

Abbott LaboratoriesAsia PacificBusiness FinanceEpilepsyGlaxoSmithKlineGlobalHealth Medical PharmaHealth Medical PharmaJohnson & JohnsonMarkets & MarketingNeurologicalNovartisPfizerPharmaceuticalUCB

Lundbeck and Otsuka file for US approval of brexpiprazole

Lundbeck and Otsuka file for US approval of brexpiprazole

14-07-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka have submitted a New Drug Application…

brexpiprazoleLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceuticalPiperidinesRegulationUSA

US psychiatrists’ views on prescribing Otsuka/Lundbeck’s brexpiprazole

26-06-2014

Surveyed US psychiatrists are receptive to novel adjunctive therapies to antidepressants for treatment-resistant…

brexpiprazoleBrintellixLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

25-06-2014

The amyotrophic lateral sclerosis (ALS) treatment market value will decline from $64 million in 2013…

EuropeJapanMarkets & MarketingNeurologicalPatentsPharmaceuticalRilutekSanofiUSA

Top 5% of opioid prescribers write 40% of US narcotic prescriptions

Top 5% of opioid prescribers write 40% of US narcotic prescriptions

09-06-2014

In the USA, 40% of narcotic prescriptions in 2011-2012 were written by only 5% of opioid prescribers,…

Markets & MarketingNeurologicalPharmaceuticalUSA

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

05-06-2014

UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

Major depressive disorder treatment market to grow to $9.7 billion by end 2023, after downturn until 2017

23-05-2014

New research forecasts that the therapeutics market for major depressive disorder (MDD) will face a dynamic…

Business FinanceGlobalGlobalDataLundbeckMarkets & MarketingNeurologicalPharmaceuticalTedatioxetineValby

Eisai’s Fycompa debuts in France following reimbursement agreement

21-05-2014

Japanese pharma company Eisai has launched its Fycompa (perampanel), the first in an entirely new class…

EisaiFranceFycompaMarkets & MarketingNeurologicalPharmaceuticalPricing

Consumption of opioid drugs in Southern Europe up by 15%, World Medicine Park congress hears

12-05-2014

The congress of the World Medicine Park, the first global forum devoted to medical sciences, this year…

EuropeMarkets & MarketingNeurologicalPharmaceutical

Topamax safety concerns as a treatment for migraines in adolescents, despite recent FDA approval

Topamax safety concerns as a treatment for migraines in adolescents, despite recent FDA approval

11-04-2014

The US Food and Drug Administration’s recent approval of Johnson & Johnson subsidiary Janssen’s Topamax…

JanssenJohnson & JohnsonMarkets & MarketingNeurologicalPharmaceuticalRegulationTopamax

Sunovion’s once-daily epilepsy drug Aptiom debuts in USA

08-04-2014

USA-based Sunovion Pharmaceuticals, a subsidiary of Japanese drug major Dainippon Sumitomo, has launched…

AptiomDainippon Sumitomo PharmaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSunovionUSA

1 to 25 of 123 results

Back to top